An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to provide biological samples from patients with
Huntington's disease to allow characterisation of the pharmacological mechanism of action of
SEN0014196.
Phase:
Phase 1
Details
Lead Sponsor:
Siena Biotech S.p.A.
Collaborators:
European Huntington's Disease Network Seventh Framework Programme